Don’t miss the opportunity to experience a showcase of 8 start-up
companies presenting innovative methods for ocular drug delivery.  We will also
feature a panel of experts who will discuss and debate the merits of various strategies.

PROUDLY SPONSORED BY:

Allergan

Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the industry.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQTM (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.

MEDIA PARTNER:

AGENDA | NOVEMBER 5

1:00 –1:05 PM

Welcome and Opening Remarks

1:05 – 1:15 PM

Drug Delivery Market Overview

1:15 – 2:15 PM

Company Showcase

2:15 – 3:00 PM

Are you a Porsche or a truck? Drug Delivery Methodologies & Strategies Panel

3:00 – 4:30 PM

Company Q&A & Virtual Networking

GET INVOLVED

Learn how your company can get involved in another successful OIS meeting.

SPONSOR THIS EVENT

Gain valuable exposure and visibility for your company's branding.

APPLY TO PRESENT

Increase awareness of your technology & the
developmental stage of your company.

SUBSCRIBE TO OUR NEWSLETTER

Weekly Newsletters About The Latest In Ophthalmic Innovation.

JOIN US ON LINKEDIN

Connect and converse with nearly 5,000
innovative ophthalmic professionals.